CNCR

Loncar Cancer Immunotherapy ETF
*Unless otherwise stated, data provided by FactSet.

CNCR Fund Description

CNCR tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs.

CNCR Factset Analytics Insight

CNCR takes an approach to niche coverage within the health care sector. It provides equal-weighted exposure to about 30 companies of various sizes that have approved immunotherapy cancer drugs on the US or European markets or that are engaged in human clinical trials of such drugs. The fund seeks a holistic exposure to the immunotherapy space, specifically including companies with varying drug mechanisms. Equal-weighting of the securities draws attention to smaller companies with room to grow. This fund provides a unique option for investors placing a highly specialized bet on this space.

CNCR MSCI ESG Analytics Insight

Loncar Cancer Immunotherapy ETF has an MSCI ESG Fund Rating of A based on a score of 6.03 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. Loncar Cancer Immunotherapy ETF ranks in the 46th percentile within its peer group and in the 89th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

CNCR MSCI FaCS and Factor Box

MSCI FaCS is a standard method for evaluating and reporting the Factor characteristics of equity portfolios including ETFs. The Factor Box includes 6 Factors that MSCI has identified that historically provided a return premium. On the vertical axis, the Factor Groups, are displayed and the horizontal axis displays the Factor exposure, overweight, underweight or neutral.

PERFORMANCE [as of 09/24/21] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
CNCR 3.65% 0.68% -1.41% 17.85% 8.39% 4.18% --
CNCR (NAV) 2.54% -2.58% -2.36% 18.88% 7.82% 3.99% --
Loncar Cancer Immunotherapy Index -- -- -- -- -- -- --
N/A -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

CNCR Summary Data

Loncar
10/13/15
Open-Ended Fund
0.79%
$44.26M
$145.61K
0.32%

CNCR Portfolio Data

$28.68B
-19.26
4.43
0.91%
N/A
30

CNCR Index Data

Equal
Market Cap
N/A

CNCR Portfolio Management

0.79%
--
--
--

CNCR Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

CNCR Fund Structure

Open-Ended Fund
No
No
-- / --
N/A
N/A
Medium
Daily

CNCR Factset Analytics Block Liquidity

As of 09/27/21
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of CNCR. CNCR is rated a 3 out of 5.

CNCR Tradability

4,877
$145.61K
2,392
$73.05K
0.32%
$0.10
-0.03%
2.17% / -1.71%
None
91.00%
50,000
0.05
0.01%
0.68%
0
$30.95
3

CNCR Sector/Industry Breakdown


CNCR
Segment Benchmark
58.84%
--
18.81%
--
10.28%
--
3.46%
--

CNCR Top 10 Holdings[View All]

5.92%
4.28%
3.81%
41.90%

CNCR Countries


CNCR
Segment Benchmark
75.97%
--
7.63%
--
3.68%
--
3.56%
--
3.47%
--
3.30%
--
2.40%
--

CNCR Regions


CNCR
Segment Benchmark
78.37%
--
10.92%
--
10.71%
--

CNCR Economic Development


CNCR
Segment Benchmark
92.37%
--
7.63%
--

CNCR Performance Statistics

--
--
--
--
0.00%
N/A

CNCR MSCI ESG Ratings

6.03 / 10
89.24
46.27
--
8.03%
21.27

CNCR Benchmark Comparison Holdings

30
--
--
0.00%

CNCR Benchmark Comparison Summary


CNCR
Segment Benchmark
30
--
$28.68B
--
-19.26
--
4.43
--
0.45%
--
Medium
High

CNCR Benchmark Comparison Market Cap Size


CNCR
Segment Benchmark
28.52%
--
26.99%
--
44.49%
--
0.00%
--